arrow
L

Lutrick, K

University of Arizona
H指数:0
被引数:6

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unveiling post-vaccination proteomic signatures in SARS-CoV-2 infection-naïve individuals associated with Omicron breakthrough infections

揭示与奥密克戎突破性感染相关的SARS-CoV-2感染-naïve个体疫苗接种后蛋白质组学特征

2026-05-110
OA
Intrinsic immunogenicity is a major determinant of type-specific responses in SARS-CoV-2 infections

固有免疫原性是SARS-CoV-2感染中类型特异性反应的主要决定因素。

2025-05-270
PRE
Estimating the generation time for influenza transmission using household data in the United States
2025-03-010
OA
Ongoing Symptoms After Acute SARS-CoV-2 or Influenza Infection in a Case-Ascertained Household Transmission Study: 7 US Sites, 2021-2023
2025-02-010
PRE
Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential Workers

信使RNA冠状病毒疾病2019 (新型冠状病毒肺炎) 疫苗接种与新型冠状病毒冠状病毒2感染后COVID后病情减少的关联

2024-11-130
OA
Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022-2023: A Prospective Cohort Study
2024-10-240
OA
Relative Effectiveness and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Versus Egg-Based Inactivated Influenza Vaccine Among Adults Aged 18-64 Years: Results and Experience From a Randomized, Double-Blind Trial

在18-64岁的成年人中,四价重组流感疫苗与基于鸡蛋的灭活流感疫苗的相对有效性和免疫原性: 一项随机,双盲试验的结果和经验

2024-09-261
OA
Reduced risk of SARS-CoV-2 infection among household contacts with recent vaccination and past COVID-19 infection: results from 2 multisite case-ascertained household transmission studies

近期接种疫苗和既往COVID-19感染者家庭接触者中SARS-CoV-2感染风险降低:来自2项多中心病例确认家庭传播研究的结果

2024-08-310
OA
Hybrid Immunity and Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: Results of the HEROES-RECOVER Prospective Cohort Study
2024-03-111
PRE
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years
2024-02-065
OA
Temporal Changes in Vaccine-Specific Willingness Across Race/Ethnicity Following Serious Adverse Event Reports
2024-01-010
OA
Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies
2023-12-016
OAAI
Symptoms, Viral Loads, and Rebound Among Coronavirus Disease 2019 (COVID-19) Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score-Matched Untreated Individuals

与倾向评分匹配的未治疗个体相比,接受尼马曲韦/利托那韦治疗的冠状病毒疾病2019 (新型冠状病毒肺炎) 门诊患者的症状,病毒载量和反弹

2023-11-1418
OA
Humoral Immune Response to Messenger RNA Coronavirus Disease 2019 Vaccination Among Children Aged 5-11 Years in a Multisite Prospective Cohort Study, September 2021-September 2022
2023-08-121
OAAI
Risk Factors for Reinfection with SARS-CoV-2 Omicron Variant among Previously Infected Frontline Workers
2023-03-0110
OAAI
Perceived Hospital Stress, Severe Acute Respiratory Syndrome Coronavirus 2 Activity, and Care Process Temporal Variance During the COVID-19 Pandemic*
2023-02-155
OAAI
Household Transmission of Influenza A Viruses in 2021-2022

2021至2022甲型流感病毒的家庭传播

2023-02-1414
OA
Severe Acute Respiratory Syndrome Coronavirus 2 Infection History and Antibody Response to 3 Coronavirus Disease 2019 Messenger RNA Vaccine Doses
2022-12-294
PRE
Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers
2022-10-1823
OA
Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers
2022-05-1229
OAAI